Effects of Cannabinoids on Menopause Symptoms
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
This study is testing whether hemp-derived cannabinoids can help women aged 40-60 manage menopause symptoms.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 40 Years to 60 Years |
| Sex | Female |
| Sponsor | Washington State University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pullman, Washington) |
| Trial ID | NCT06831916 on ClinicalTrials.gov |
What this trial studies
This study examines how hemp-derived minor cannabinoids affect symptoms associated with menopause and perimenopause in women aged 40-60. It employs a randomized, double-blind, placebo-controlled design over a three-month period. Participants will undergo cognitive testing and will be required to abstain from regular cannabis use during the study. Recruitment will occur through various channels, including social media and menopause conferences.
Who should consider this trial
Good fit: Ideal candidates are healthy adult women aged 40-60 experiencing psychological and physical symptoms of menopause or perimenopause.
Not a fit: Patients currently taking antidepressants, antipsychotics, or those with severe mental health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel therapeutic option for managing menopause symptoms in women.
How similar studies have performed: While cannabinoid treatments are being explored for various conditions, this specific approach to menopause symptoms is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * designated female at birth * 40-60 years of age * able to give informed consent (no intellectual disability) * stable pharmacotherapeutic regimen, no change in the past 3 months * abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months * abstinent for supplements, don't add any supplements (no changes in past 3 months) * own a smartphone * have access to Zoom on a secure, stable internet connection * perimenopausal or menopausal Exclusion Criteria: * currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication * severe depression, neurovegetative symptoms, or current suicidality * psychosis or family history of psychosis * pregnant or breastfeeding * chemotherapy * hypotension * drug testing for work or other reasons * illicit drug use in past 3 months (cannabis not illicit) * heavy alcohol use (4 drinks more than 4x/week) * international/air travel planned for more than one week in the next 3 months
Where this trial is running
Pullman, Washington
- Washington State University - Pullman Campus — Pullman, Washington, United States (Recruiting)
Study contacts
- Study coordinator: Carrie Cuttler, Ph.D., Psychology
- Email: carrie.cuttler@wsu.edu
- Phone: (509) 592-0151
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.